Whatever the origin of the
coronavirus, it is and has become a bioweapon. Way before Bill Gates warned us in 2015 about biological pandemics, biological
warfare an emerging threat in the 21st century was the topic of the article above in 2001.
We also have to realise that four years ago Central Intelligence Agency Director John Brennan said at the Council on Foreign Relations that “
advances in genome editing pose a threat to national security and may be used to create biological weapons .
Nowhere are the stakes higher for our national security than in the field of biotechnology, Brennan stated.
Recent advances in genome editing that offer great potential for breakthroughs in public health are also a cause for concern because the same methods can be used to create genetically engineered biological warfare agents.”
The Streetjournal Magazine is an online investigating media house that specializes on systematic, serious crimes, political corruption or corporate wrongdoing.
May 12, 2021
Over nearly two decades, a new study has found, government agencies have given at least £175 million ($248 million) to develop ChAdOx, a vaccine delivery system developed by scientists at Oxford University. Charities like the Wellcome Trust have given at least a further £53 million. As much as 99% of the total disclosed funding for ChAdOx research came from public or philanthropic money. And yet ChAdOx now sits at the heart of AstraZeneca’s Covid-19 vaccine, and the company is free to profit from it at will.
To be sure, AstraZeneca has said it will sell these vaccines at no profit to the developing world “in perpetuity,” and at no profit in the West until it decides the pandemic is over. But that could be as soon as July after which AstraZeneca can cash in heavily on these years of publicly funded research, just as its competitors, such as Pfizer and Moderna, are already doing.
May 11, 2021 Share
A gene therapy that makes use of an unlikely helper, the AIDS virus, gave a working immune system to 48 babies and toddlers who were born without one, doctors reported Tuesday.
Results show that all but two of the 50 children who were given the experimental therapy in a study now have healthy germ-fighting abilities.
“We’re taking what otherwise would have been a fatal disease” and healing most of these children with a single treatment, said study leader Dr. Donald Kohn of UCLA Mattel Children’s Hospital.
“They’re basically ‘free range’ going to school, doing normal things,” without the worry that any infection could become life-threatening, he said.
Share this article
Share this article
COLLEGE STATION, Texas, May 12, 2021 /PRNewswire/ Matica Biotechnology, Inc. (Matica Bio) today announced that the Board of Directors has appointed Yun Jeong Song, MD, as the company s new Chief Executive Officer (CEO) to continue its expansion as a CDMO supporting the global cell and gene therapy industry. Dr. Song joined the company effective April 1
st, 2021 after 3 years as CEO of ImmuneOncia Therapeutics, an international joint venture developing immuno-oncology therapies. Dr. Song succeeds Byung Se So, PhD, who will remain with Matica Bio as an advisor.
Matica Biotechnology GMP Facility (College Station TX, USA)
Dr. Song s background spans more than 20 years of basic research, patient care and biopharmaceutical industry leadership. Prior to ImmuneOncia Therapeutics, she held positions at the U.S. National Institutes of Health, Samsung, and Sanofi.